133 related articles for article (PubMed ID: 28196215)
1. Headache in the Setting of Immunotherapy Treatment for Metastatic Melanoma.
Comstock DE; Nishino M; Giardino AA
JAMA Oncol; 2017 May; 3(5):703-704. PubMed ID: 28196215
[No Abstract] [Full Text] [Related]
2. Checkpoint Inhibitor-Associated Hypophysitis.
Chang LS; Yialamas MA
J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
[No Abstract] [Full Text] [Related]
3. The dynamics of medical care in skin cancers.
Dummer R
Curr Opin Oncol; 2018 Mar; 30(2):105-106. PubMed ID: 29303788
[No Abstract] [Full Text] [Related]
4. Superior Pituitary Border Analysis in Immunotherapy-Induced Hypophysitis.
Pucar D; Boustani AM; Bronen RA; Saperstein L
Clin Nucl Med; 2018 Apr; 43(4):284-286. PubMed ID: 29401149
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity.
Philipp M; Frischhut N; Tschachler A; Steinkohl F; Weinlich G; Schmuth M; Nguyen VA
Anticancer Drugs; 2018 Oct; 29(9):914-918. PubMed ID: 29952773
[TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
8. Case of hypophysitis caused by nivolumab.
Ishikawa M; Oashi K
J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
[No Abstract] [Full Text] [Related]
9. Hypophysitis on immunotherapy with checkpoint inhibitors.
Jäger IM; Kohlmann J; Simon JC; Sandner B; Tönjes A; Ziemer M
J Dtsch Dermatol Ges; 2019 Nov; 17(11):1168-1170. PubMed ID: 31701648
[No Abstract] [Full Text] [Related]
10. Dose-dependent toxicity of ipilimumab in metastatic melanoma.
Olischewsky A; De Schrijver S; Bankfalvi A; Wetter A; Zimmer L; Livingstone E; Schadendorf D; Ugurel S
Eur J Cancer; 2018 May; 95():104-108. PubMed ID: 29477367
[No Abstract] [Full Text] [Related]
11. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
12. Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Tétu P; Mangana J; Dummer R; Dutriaux C; Beneton N; Dalle S; Meyer N; Oriano B; Michielin O; Lebbe C
Eur J Cancer; 2018 Apr; 93():147-149. PubMed ID: 29449059
[No Abstract] [Full Text] [Related]
13. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.
Chapman PB; D'Angelo SP; Wolchok JD
N Engl J Med; 2015 May; 372(21):2073-4. PubMed ID: 25891305
[No Abstract] [Full Text] [Related]
14. Drastic effect on giant lung metastatic melanoma by sequential administration of nivolumab with ipilimumab/radiation combination therapy.
Komori T; Otsuka A; Irie H; Horiguchi A; Honda T; Kabashima K
J Dermatol; 2018 Jan; 45(1):e7-e8. PubMed ID: 28980713
[No Abstract] [Full Text] [Related]
15. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
16. [Histoseminar on inflammatory bowel diseases (IBD): Case n
Fléjou JF
Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitor-induced hypophysitis.
Dudoignon D; Guégan S; Barat M
Diagn Interv Imaging; 2021 Nov; 102(11):697-698. PubMed ID: 33985923
[No Abstract] [Full Text] [Related]
18. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.
Satzger I; Ivanyi P; Länger F; Kreipe HH; Schaper-Gerhardt K; Beutel G; Cornberg M; Gutzmer R
Eur J Cancer; 2018 Apr; 93():150-153. PubMed ID: 29472154
[No Abstract] [Full Text] [Related]
19. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
